AvenCell Therapeutics recently announced that the first patient has been dosed in a Phase 1A study with its lead product candidate AVC-201. This novel...

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

In this article, we look at recent clinical updates from the gene-editing field. These updates include clinical data from Vor Bio's ongoing Phase 1/2a...

Leading epigeneticist Gabriella Ficz has used CRISPR technology to investigate the interplay between DNA methylation and cancer. Her latest findings...

Beam Therapeutics reports dosing of the first patient with BEAM-201, a multiplex-edited allogeneic CAR-T cell candidate developed to treat relapsed or...

AvenCell Therapeutics announces that the European Medicines Agency has approved its clinical trial application for AVC-201, a novel CRISPR-edited and...

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...